Literature DB >> 15175417

Isobolographic analysis for combinations of a full and partial agonist: curved isoboles.

Yury Grabovsky1, Ronald J Tallarida.   

Abstract

Combinations of drugs are frequently used therapeutically to achieve an enhanced effect without using an excess quantity of either agent. If the drugs exert overtly similar action, e.g., two analgesics, the effect of the combination may be tested for additivity, i.e., an effect level that is achieved based on the individual drug potencies. But combinations of agonists will sometimes display either superadditive (synergistic) or subadditive responses. Whether the two agonists are both drugs, or a combination of a drug and an endogenous chemical, there is interest in characterizing the interaction to determine whether it departs from additivity because quantitative information of this kind, aside from its therapeutic importance, may also illuminate mechanism. A common method for this characterization uses the isobologram. This is a plot in rectangular coordinates of dose combinations (a,b) that produce the same effect level (often taken to be 50% of the maximum). In its usual form, this plot is constructed as a straight line (of additivity) connecting intercepts that represent the individually effective doses, e.g., ED50 values of each. This line is the reference for distinguishing additive from nonadditive interactions accordingly as the tested combination is on or off this line. Discussed here are the assumptions that underlie this linear plot. Specifically we show that a combination of drugs with a variable potency ratio, exemplified by a full and a partial agonist, lead to curvilinear isoboles of additivity that may erroneously be attributed to either synergism or subadditivity.

Mesh:

Substances:

Year:  2004        PMID: 15175417     DOI: 10.1124/jpet.104.067264

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  67 in total

Review 1.  Revisiting the isobole and related quantitative methods for assessing drug synergism.

Authors:  Ronald J Tallarida
Journal:  J Pharmacol Exp Ther       Date:  2012-04-17       Impact factor: 4.030

2.  Quantitative methods for assessing drug synergism.

Authors:  Ronald J Tallarida
Journal:  Genes Cancer       Date:  2011-11

Review 3.  The determination and application of fixed-dose analgesic combinations for treating multimodal pain.

Authors:  Robert B Raffa; Joseph V Pergolizzi; Ronald J Tallarida
Journal:  J Pain       Date:  2010-03-24       Impact factor: 5.820

4.  Nonlinear isobologram and superadditive withdrawal from cocaine: cannabinoid combinations in planarians.

Authors:  Robert B Raffa; Gregory W Stagliano; Ronald J Tallarida
Journal:  Eur J Pharmacol       Date:  2006-10-27       Impact factor: 4.432

Review 5.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

6.  Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.

Authors:  Ewelina Gumbarewicz; Jarogniew J Luszczki; Anna Wawruszak; Magdalena Dmoszynska-Graniczka; Aneta J Grabarska; Agata M Jarząb; Krzysztof Polberg; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

7.  Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves.

Authors:  Jarogniew J Luszczki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-20       Impact factor: 3.000

8.  Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.

Authors:  John C Oakley; Alvin R Cho; Christine S Cheah; Todd Scheuer; William A Catterall
Journal:  J Pharmacol Exp Ther       Date:  2013-02-19       Impact factor: 4.030

9.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Authors:  Lesley A Mathews Griner; Rajarshi Guha; Paul Shinn; Ryan M Young; Jonathan M Keller; Dongbo Liu; Ian S Goldlust; Adam Yasgar; Crystal McKnight; Matthew B Boxer; Damien Y Duveau; Jian-Kang Jiang; Sam Michael; Tim Mierzwa; Wenwei Huang; Martin J Walsh; Bryan T Mott; Paresma Patel; William Leister; David J Maloney; Christopher A Leclair; Ganesha Rai; Ajit Jadhav; Brian D Peyser; Christopher P Austin; Scott E Martin; Anton Simeonov; Marc Ferrer; Louis M Staudt; Craig J Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

10.  Assessment of combined antiandrogenic effects of binary parabens mixtures in a yeast-based reporter assay.

Authors:  Dehua Ma; Lujun Chen; Xiaobiao Zhu; Feifei Li; Cong Liu; Rui Liu
Journal:  Environ Sci Pollut Res Int       Date:  2014-01-28       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.